Wealthspring Capital’s European Biotech Acquisition Corp. Units EBACU Stock Holding History

Wealthspring Capital’s Portfolio EBACU Stock Details EBACU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-68,613	Closed	-$680K	–	394
2022 Q3	$680K	Sell	68,613 -9,260	-12%	-$91.6K	0.13%	254
2022 Q2	$760K	Sell	77,873 -3,610	-4%	-$35.5K	0.14%	242
2022 Q1	$797K	Sell	81,483 -800	-1%	-$7.91K	0.16%	226
2021 Q4	$816K	Sell	82,283 -12,617	-13%	-$125K	0.17%	209
2021 Q3	$940K	Buy	94,900 +40,253	+74%	+$400K	0.23%	155
2021 Q2	$545K	Buy	54,647 +36,977	+209%	+$370K	0.14%	194
2021 Q1	$177K	Buy	+17,670	New	+$177K	0.05%	269

Other funds holding EBACU

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

LCM

Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return

TAM

Terrapin Asset Management Miami, Florida $87.8M AUM 16.84% 1-Year Est. Return

Wealthspring Capital's EBACU Position: Q4 2022 in Review

Wealthspring Capital sold out of European Biotech Acquisition Corp. Units (EBACU) in Q4 2022, closing a stake of 68,613 shares — an estimated $680K sold.

Wealthspring Capital first reported a position in EBACU in Q1 2021 and held it in 7 quarters. The position peaked at $940K in Q3 2021. 11 funds tracked by Wall St. Rank hold EBACU as of Q4 2022.

Wealthspring Capital reported no remaining European Biotech Acquisition Corp. Units position as of Q4 2022 after selling out during the quarter.
Wealthspring Capital sold 68,613 European Biotech Acquisition Corp. Units shares in Q4 2022, an estimated $680K.
Wealthspring Capital first reported a position in European Biotech Acquisition Corp. Units in Q1 2021 and held it in 7 quarters.
Wealthspring Capital's European Biotech Acquisition Corp. Units position peaked at $940K in Q3 2021.
11 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Units as of Q4 2022.

Based on Wealthspring Capital's 13F filing for Q4 2022, filed 8 Feb 2023.